ATUM Announces Leap-In Transposase Licensing Agreement with Codiak Biosciences to Support Manufacturing of Exosome-Based Therapeutics
ATUM, a global specialist and industry leader in bioengineering solutions,announced the signing of a full licensing agreement for the Leap-In Transposase technology with Codiak BioSciences, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics, a new class of medicines.
“Exosomes are bio vesicles that have the potential to fundamentally change drug delivery. We are proud and excited to license the Leap-In Transposase® technology to Codiak for the engineering of cell lines that enables rapid and robust production of exosomes.”
Under the terms of the agreement, ATUM will provide Codiak access to its Leap-In Transposase technology to generate mammalian cells expressing exosomes engineered to deliver therapeutic payloads. The Leap-In technology is an integrated solution combining proprietary re-coding algorithms, unique genetic vector elements as well as a transposon-based mechanism for efficient insertion of genetically stable elements into the genome.
Recommended AI: Himax Partners with Novatek to Unveil Industry Leading Ultralow Power Pre-Roll AI Solution for Battery Surveillance Camera
Scott Estes, Ph.D., VP of Cell Line Development at Codiak, said, “Through years of rigorous research and clinical validation we have created a platform for engineering and manufacturing therapeutic exosomes with various payloads on the surface or inside the lumen. We believe ATUM’s transposase technology has the potential to effectively synergize with Codiak’s engEx Platform to further enhance loading these vesicles, making them more potent and reducing cost of goods.”
Recommended AI: Himax Partners with Novatek to Unveil Industry Leading Ultralow Power Pre-Roll AI Solution for Battery Surveillance Camera
Claes Gustafsson, Ph.D., Chief Commercial Officer and Co-Founder at ATUM, commented, “Exosomes are bio vesicles that have the potential to fundamentally change drug delivery. We are proud and excited to license the Leap-In Transposase technology to Codiak for the engineering of cell lines that enables rapid and robust production of exosomes.”
Recommended AI: aelf Announces the form of aelf DAO, Enhancing Decentralization of Governance and Ecosystem Growth
[To share your insights with us, please write to sghosh@martechseries.com]
Comments are closed.